Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Clin Infect Dis ; 68(Suppl 1): S42-S45, 2019 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-30766999

RESUMO

Recognizing that enteric fever disproportionately affects the poorest and the most vulnerable communities that have limited access to improved sanitation, safe water sources, and optimal medical care, the Bill & Melinda Gates Foundation has funded efforts to augment global understanding of the disease since the foundation's inception. At the turn of the century, early efforts focused on characterizing the burden of disease in Asia and evaluating use of the available Vi-polysaccharide vaccines through the Diseases of the Most Impoverished projects at the International Vaccine Institute (IVI). More recent efforts have centered on supporting development of typhoid conjugate vaccines and expanding disease surveillance efforts into Africa, as well as generating a greater understanding of the clinical severity and sequelae of enteric fever in Africa, Asia, and India. The Typhoid Vaccine Accelerator Consortium is playing a critical role in coordinating these and other global efforts for the control of typhoid fever. Here, we outline the scope of support and strategic view of the foundation and describe how, by working through strong partnerships, we can realize a radical reduction of the significance of enteric fever as a global public health problem in the next 10 to 15 years.


Assuntos
Fundações , Febre Tifoide/epidemiologia , Febre Tifoide/prevenção & controle , Vacinas Tíficas-Paratíficas/imunologia , Saúde Global , Humanos , Pobreza , Febre Tifoide/economia
2.
Clin Infect Dis ; 69(Suppl 5): S408-S411, 2019 10 15.
Artigo em Inglês | MEDLINE | ID: mdl-31612940

RESUMO

With a newly World Health Organization (WHO)-prequalified typhoid conjugate vaccine (TCV), Gavi funding for eligible countries, and a WHO policy recommendation for TCV use, now is the time for countries to introduce TCVs as part of an integrated typhoid control program, particularly in light of the increasing burden of antimicrobial resistance. Continued vaccine development efforts will lead to secure supply of low-cost vaccines, and ongoing vaccine studies will provide critical vaccine performance data and inform optimal deployment strategies, in both routine use and in outbreak settings. TCV programs should include thoughtful communication planning and community engagement to counter vaccine hesitancy.


Assuntos
Saúde Global , Febre Tifoide/prevenção & controle , Vacinas Tíficas-Paratíficas/administração & dosagem , Vacinação/normas , Organização Mundial da Saúde , Controle de Doenças Transmissíveis/legislação & jurisprudência , Controle de Doenças Transmissíveis/organização & administração , Controle de Doenças Transmissíveis/normas , Surtos de Doenças/prevenção & controle , Humanos , Salmonella typhi/imunologia , Saneamento , Vacinas Tíficas-Paratíficas/economia , Vacinas Tíficas-Paratíficas/normas , Vacinação/legislação & jurisprudência , Vacinação/estatística & dados numéricos , Vacinas Conjugadas/administração & dosagem , Água
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA